drugset
drugset / Trial / NCT06926842

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

NCT06926842 ↗

Phase 2 Active not recruiting 221 enrolled Zealand Pharma Parexel · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.

Timeline

Start
2025-04-22
Primary completion
2026-08-13
Completion
2026-08-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Petrelintide Protein / enzyme biologic — Subcutaneous

Indications

obesity disorder type 2 diabetes mellitus